Stock Price
2.33
Daily Change
-0.04 -1.69%
Monthly
-20.48%
Yearly
76.52%
Q2 Forecast
2.28

Galectin Therapeutics reported $61K in Ordinary Share Capital for its fiscal quarter ending in December of 2023.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Gilead Sciences USD 1.24B 1000K Dec/2025
Immunic USD 8K 4K Jun/2024
Incyte USD 198.46M 2.33M Dec/2025
Merck USD 2.49B 15.79M Sep/2025